Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. Read more about Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232.
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Read more about Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples. Read more about Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples.
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Read more about Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age. Read more about Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Read more about Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. Read more about Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group.
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Read more about FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Read more about Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells. Read more about H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
